Navigation Links
Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer

grineinc.com/http://www.avidbio.com/">http://www.peregrineinc.com/http://www.avidbio.com/

Ticker Symbol: (NASDAQ-NMS:PPHM)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes

Post Your Comments:
(Date:11/25/2009)...stCall/--ERT(Nasdaq: ERES ),announcedtodaythatDr.M...ithSchneck,theCompany,sExecutiveVicePresidentandCF...HealthCareConferenceat1:30PMESTonDecember1,2009inN...ssthepresentationbyvisitingtheCompany,scorporatewe...essedat http://www.corporate-ir.net/ireye/conflobb...
(Date:11/25/2009)...USNewswire/--RemediumTechnologiesInc.,acompanydeve...g,wonfirstprizeand$10,000intheMostPromisingSecurit...anyofficialsannouncetoday. ,, Selectedfrommoret...hedtheirinventionattheGSCSecuritySummitconferenceh...w.remediumtechnologies.com )isdevelopingahigh-pres...
(Date:11/25/2009)...linker.comannouncesthatanewmarketresearchreportisa...nt-AGlobalMarketPerspective ,, http://www.re...Global-Market-Perspective.html ,, Risingincide...gnationsisaprincipalfactorinfluencinggrowthinthema...reastcancerhasallowedwomentocomeforwardfortheiryea...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Extending treatment after liver transplant may benefit patients with hepatitis C recurrence 60452 1Extending treatment after liver transplant may benefit patients with hepatitis C recurrence 60452 2Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 1Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 2Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 3BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 1BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 2BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 3BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 4BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 5BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 6BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 7
...tro Assays Show rBChE Suppresses Amyloid Plaque,Fo...ene, Inc., a leading,biodefense company specializi...ical countermeasures against chemical and,biologic...ts,recombinant butyrylcholinesterase (rBChE) resea...ernational Conference on,Alzheimer,s and Parkinson...
...T, N.J., April 04, 2007 /PRNewswire-FirstCall/ -- ...perative Oncology Group,(ECOG) has reported that i...liminary results from a large, randomized clinical...myeloma has found,that the use of a low dose of de...omide suggests survival advantage for,patients whe...
Other Medicine Technology:Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 2ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 3ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 4ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 5ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 7
(Date:11/27/2009)... Biotech firm Replikins Ltd. tod...1N1 virus genomic data. It shows that the lethali...s.d. 4.5) during the virus,s current outbreak in t...his week of 2.0 (s.d. 0.1). The H1N1 infectivity c... Boston (PRWEB) November 27, 2009 -- Bio...
(Date:11/27/2009)... NEUILLY-SUR-SEINE,France,Nov.27/PRNewswire/--Team...ingteamdedicatedtoethicalsportinganddevelopingthen...itwillbecomeTeamGarmin-Transitionswiththeadditiono...onsOpticalistheworld,sleadingmanufacturerofadaptiv...logyinthewidestselectionofspectaclelensessuchasTra...
(Date:11/27/2009)... rates to bring unprecedented medical, economic bu...7 (HealthDay News) -- The number of people with di...over the next 25 years, a new study predicts. ,...million people with the disease, up from 23.7 mill...ating people with diabetes will triple, the study ...
(Date:11/27/2009)... Specialist manufacturers who us...s are saving millions of dollars by bringing in te...ss. Increasing numbers of pro-active medical manuf...at the concept stage of their projects, ensuring t...esign processes or potentially outdated technology...
(Date:11/26/2009)...e next 25 years, the number of Americans living wi....7 million in 2009 to 44.1 million in 2034. Over t...riple, rising from $113 billion to $336 billion, e... researchers based at the University of Chicago re... The number of those with diabetes covered by Medi...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3
...ent an important contribution to future clinical t...the prestigious science journal Nature and will ...on the molecular mechanisms of hematopoiesis, whic...n Munich at the international symposium "Molecular...
...sAbilities Resources champions company,s efforts ,...ed the 2009 Disability Matters Award in the catego...ment to supporting people with disabilities and th...and its employee network group, Sodexo Organizatio...
... to treat a mid-level, common injury , , ROSEMON...ions can commonly be treated nonsurgically and hig...re review published in the April 2009 issue of the...se injuries that fall in between. , , , , ...
... Immunotech Laboratories, Inc. , , Immunotech La...DART conference in Puerto Rico with its abstract ...ificant antiretroviral activity via specific novel...ence on Clinical and Social Research on AIDS and D...
... Awareness among Hispanic Community as Fewer Recei...Easter Seals is shining the spotlight on its servi...vast array of services, the national nonprofit pro...ren and adults with autism the organization serves...
..., Self-administered Alternative to Injections for ... LAKE, N.J., April 1 Strativa Pharmaceuticals, th...subsidiary of Par Pharmaceutical Companies, Inc. (...Nasal Spray is an FDA approved prescription vitami...
Other Medicine News:Health News:Last step leading to blood cell formation elucidated 2Health News:Sodexo Receives 2009 Disability Matters Award 2Health News:Sodexo Receives 2009 Disability Matters Award 3Health News:Healing a Shoulder Separation 2Health News:Healing a Shoulder Separation 3Health News:Beating a Global Killer: HIV/AIDS 2Health News:Beating a Global Killer: HIV/AIDS 3Health News:Beating a Global Killer: HIV/AIDS 4Health News:Easter Seals Notes April's Autism Awareness Month to Highlight Services Available to Families Living With Autism 2Health News:Easter Seals Notes April's Autism Awareness Month to Highlight Services Available to Families Living With Autism 3Health News:Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical 2Health News:Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical 3Health News:Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical 4
...BAK/C cervical interbody fusion system represents ...ive disc disease of the cervical spine. The system...ration, and implantation. The self-packing of bone...raft, eliminating the need to harvest from the ili...
Intera 3.0T
...The Intradiscal Instruments are designed to provid...sc removal, endplate preparation, and insertion of...tebral Spreaders, Intradiscal Wedges, Spanners, Ne...er. Used in ALIF (Anterior Thoracic Interbody Fusi...
...Symphony II Platelet Concentrate System is a point... of Platelet Concentrate (also referred to as Plat...PPP) from a small sample of blood. The Symphony II...s, which are found in the platelets. The platelet ...
Medicine Products: